Clinical trial / 2019
Nicotinamide riboside chloride dose-dependently increased whole blood NAD+ within 2 weeks and was well tolerated over 8 weeks in healthy overweight adults.
An 8-week randomized, double-blind, placebo-controlled trial evaluated the safety and oral availability of nicotinamide riboside chloride (NIAGEN) in overweight, healthy men and women. Daily consumption of 100, 300, and 1000 mg NR dose-dependently and significantly increased whole blood NAD+ by 22%, 51%, and 142% within 2 weeks, with increases maintained for the remainder of the study. No flushing occurred, and adverse events did not differ significantly between NR and placebo groups or across doses. Additionally, NR did not elevate LDL cholesterol or dysregulate 1-carbon metabolism.
- Study type
- 8-week randomized, double-blind, placebo-controlled clinical trial
- Who was studied
- Overweight, but otherwise healthy men and women (sample size not stated)
- What was measured
- Kinetics, dose-dependency of oral availability (whole blood NAD+), safety
THE PAPER
Safety and Metabolism of Long-term Administration of NIAGEN (Nicotinamide Riboside Chloride) in a Randomized, Double-Blind, Placebo-controlled Clinical Trial of Healthy Overweight Adults.
Conze D, Brenner C, Kruger CL. Sci Rep, 2019.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.